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The current standard of care for hepatitis C infection is pe-
ginterferon/ribavirin (PegIFN/RBV). We are entering the era 
where direct-acting antiviral agents (DAAs) will be added to 
PegIFN/RBV, leading to higher sustained response rates in 
genotype 1 infected individuals. Currently DAAs are directed 
toward specific proteins involved in hepatitis C replication 
with NS3/NS4A protease inhibitors furthest in development. 
Telaprevir and boceprevir are both NS3/NS4a inhibitors 
that significantly improve sustained response when added 
to PegIFN and RBV. The hepatitis C virus (HCV) polymerase 
inhibitors are another promising DAA class. These molecules 
are divided into nucleoside/nucleotide polymerase inhibitors 
and nonnucleotide/nucleoside polymerase inhibitors. Nucle-
oside/nucleotide polymerase inhibitors have a high barrier to 
resistance and appear to be effective across a broad range 
of genotypes. Nonnucleoside polymerase inhibitors have a 
lower barrier of resistance and appear to be genotype spe-
ciﬁ  c. Preliminary data with these compounds are also prom-
ising. A third class, NS5A inhibitors, has also shown potent 
HCV RNA suppression in preliminary studies as monotherapy 
and with PegIFN and RBV. Combinations of these agents are 
also entering clinical trials and indeed a preliminary report 
has demonstrated that the combination of an NS3/4A prote-
ase inhibitor and NS5B polymerase inhibitor can effectively 
suppress virus in genotype 1 individuals. Future studies will 
concentrate on combinations of direct-acting antiviral agents 
without and with PegIFN and RBV. Clinicians will need to be 
familiar with managing side effects as well as resistance as 
we enter this new era. (Gut Liver 2011;5:406-417)
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INTRODUCTION
The hepatitis C virus (HCV) is the most common blood born 
infection worldwide, and is a major cause of chronic liver 
disease leading to death from liver failure or hepatocellular 
carcinoma. The current paradigm for HCV treatment relies on 
pegylated interferon (PegIFN) and ribavirin (RBV) as agents that 
enhance endogenous mechanisms for viral clearance and are 
dependent on host factors. In patients with genotype 1 HCV 
infection, which comprises the majority of patients infected in 
most of the world, including Asia, North America, and Europe, 
sustained viral response (SVR) rates remain suboptimal with 
less than half of genotype 1 infected individuals going on to 
achieve SVR. This has led to a shift in the investigational focus 
for treatment of HCV towards direct acting anti-viral agents 
(DAA) or specifically targeted antiviral therapy for HCV (STAT-C) 
agents. This review will focus on the HCV protease and poly-
merase inhibitors in development for the treatment of hepatitis 
C infection, discussing their mechanisms of action, therapeutic 
advantages and disadvantages, and current status in therapeutic 
armamentarium for anti-HCV therapy.
REPLICATION CYCLE OF HCV
The HCV is a single-stranded RNA molecule that is approxi-
mately 9,600 nucleotides in length.
1 The hepatitis C life cycle is 
similar to many positive strain RNA viruses and the replication 
cycle and targets for therapy are shown in Figs 1 and 2.  
PROTEASES AS POTENTIAL TARGETS OF ANTI-HCV 
THERAPY
Preclinical data demonstrated the role of the NS3/4A prote-
ase as chimpanzees inoculated with HCV containing defective 
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NS3/4A activity did not demonstrate HCV RNA replication.
2 The 
initial proof of principle that addition of NS3/4A protease could 
efficiently and effectively suppress HCV RNA replication was 
established by administration of the NS3/4A inhibitor BILN2061 
for 2 days in genotype 1 patients with chronic hepatitis C, 
which led to reductions of 100-1,000 fold in all individuals.
3 
This molecule BILN2061 did not receive further development 
due to concerns over cardiac toxicity.
DAA
Telaprevir (VX950; Vertex Pharmaceuticals, Cambridge, MA, 
USA) and boceprevir (SCH503034; Merck, Kenilworth, NJ, USA) 
are both peptidomimetic inhibitors of the NS3/4A protease that 
are currently in phase 3 trials and other agents are in earlier 
phase trials (Table 1). Both show substantial potential to favor-
ably impact SVR rates when added to PegIFN and RBV. Tela-
previr, a selective peptidomimetic inhibitor of HCV NS3/NS4A 
Fig. 1. Hepatitis C virus (HCV) infection and replication: targets for therapy. The virus enters the cell through attachment entry and fusion and un-
dergoes transcription to form a complementary negative sense RNA molecule which serves as the template for positive stranded RNA molecules. 
This HCV RNA reading frame contains approximately 9,000 nucleotides and generates 3 structural proteins, 6 nonstructural (NS) proteins, and 2 
proteins of unclear function. The most advanced therapies in the direct-acting antiviral drug development are directed toward the NS3/NS4A ser-
ine protease. The structural proteins are used to assemble new viral particles and the NS proteins support viral RNA replication. The NS3/4A is a 
serine protease (NS3) and cofactor (NS 4A) that catalyzes the post-translational processing of NS proteins from the polyprotein which is important 
for viral replication. The NS3 protease cleaves NS4A-NS4B, NS4B-NS5A and NS5A-NS5B junctions. The products released go on to form a rep-
licative complex responsible for forming viral RNA providing an ideal target for anti-viral therapy HCV RNA replication primarily depends upon 
the RNA dependent/RNA polymerase (NS5B). X-ray crystallography has demonstrated that the NS5B polymerase has a classical fingers, palm, and 
thumb structure providing multiple areas for therapeutic targets. Another key structure in HCV replication is the NS5A protein, though the mecha-
nisms by which NS5A regulates HCV RNA replication are less clear. It appears to have a key role in formation of the replication complex as well 
as interact with the NS5B polymerase. Viral assembly and release involves the HCV core protein and to date, therapeutic targets have not shown 
significant antiviral efficacy.
Fig. 2. Potential sites for develop-
ment of inhibitors of hepatitis C 
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protease forms a covalent, reversible complex with the NS3/4A 
protease (Fig. 3). In vitro data with genotype 1b replicons dem-
onstrated a 4 log reduction in HCV RNA level. 
1. Telaprevir
1) Phase 1 studies
An initial phase 1B dose finding study with 14 days of tela-
previr monotherapy replicated the in vitro findings. Patients 
who were both naïve and had failed previous antiviral therapy 
with PegIFN/RBV were randomized to receive telaprevir or pla-
cebo at a dose of 450 mg q8h, 750 mg q8h, or 1,250 mg q12h.
4 
The study demonstrated that the 750 mg q8h dose displayed 
the highest trough plasma concentrations with a median reduc-
tion in 14 days of 4 log10 and HCV RNA became undetectable 
in 2 individuals. In the other 2 dosing regimens, viral rebound 
was seen and was later seen to be associated with the develop-
ment of telaprevir resistant variants. A second phase 1 study 
confirmed that PegIFN alfa-2a 180 μg could be combined with 
telaprevir for 14 days at a loading dose of 1,250 mg followed by 
750 mg q8h. In this study, 60% of 15 participants who received 
telaprevir or telaprevir/PegIFN before treatment with standard 
HCV therapy achieved SVR.
5
2) Phase 2 studies: treatment of naïve patients
These phase 1 studies allowed the development of phase 2 
telaprevir studies in naïve HCV patients, the Prove 1 and Prove 
2 studies. The Prove 1 study, the first North American multi-
center telaprevir trial demonstrated the potent antiviral effects 
of telaprevir 750 mg q8h when given in combination with 
PegIFN and RBV.
6 Two hundred fifty genotype 1 HCV infected 
individuals were randomized to receive telaprevir 750 mg q8h 
weekly with PegIFN alfa-2a 180 μg and RBV1,000 to 1,200 mg 
for 12 weeks followed by none, 12, or 36 additional weeks of 
PegIFN/RBV. Patients randomized to the 12- and 24-week du-
ration arms were eligible to stop treatment at early time points 
only if HCV RNA was undetectable at week 4 which was the 
first use of a response guided paradigm with a DAA. The control 
arm was PegIFN2a/RBV for 48 weeks. Twelve weeks of PegIFN/
RBV, and telaprevir followed by 12 weeks of PegIFN/RBV led to 
an overall SVR rate of 61% vs the control 48-week PegIFN/RBV 
SVR rate of 41%. Extending therapy with PegIFN/RBV for an 
additional 24 weeks improved the SVR rate to 67% with a re-
lapse rate of 6%. The 12-week cohort, while small, nonetheless 
had a SVR rate of 35%. Both the 24- and 48-week treatment 
arms were superior to 48 weeks of PegIFN/RBV. Similar results 
were seen in the European study, Prove 2.
7 In this study, 332 
European patients were randomized to 1 of 4 treatment groups 
including 12 weeks of telaprevir, PegIFN alfa-2a 180/RBV. The 
24-week therapy consisted of telaprevir plus PegIFN/RBV for 12 
weeks followed by 12 additional weeks of PegIFN/RBV, and fi-
nally a RBV sparing arm consisting of 12 weeks of PegIFN and 
telaprevir. Similar to Prove 1 results, high RVR rates were seen 
in the telaprevir based arms (74% vs 14%). The SVR rate in 12-
week based triple combination arm with telaprevir, PegIFN/RBV 
was 60% and the 24-week treatment arm which consisted of 12 
weeks of telaprevir dosed in combination with PegIFN/RBV and 
additional 12 weeks of PegIFN/RBV alone was 69%. These regi-
mens were superior to the control arm with PegIFN/RBV with 
SVR rate of 46%. This study also demonstrated an important 
concept in that elimination of RBV markedly reduced the SVR 
rate with an overall SVR of 36% with high breakthrough and 
relapse rates in the ribavirin-sparing arm. 
3) Phase 2 studies: treatment of nonresponders
The recently published Prove 3 study evaluated the role of 
telaprevir-based regimens in genotype 1 HCV patients who did 
Table 1. NS3-4a Protease Inhibitors in Development
Protease compound Company Phase Other
BILN 2061 Boehringer Ingelheim 1 Stop Heart toxicity
Telaprevir Vertex/Tibotec 3
Boceprevir Merck 3
ACH-806 Achillion 1 Stop Renal toxicity
ITMN 191/R7227 InterMune/Roche 2
TMC435350 Medivir/Tibotec JJ 2
BI 201335  Boehringer Ingelheim 2
MK7009 Merck 2
Several compounds will report sustained viral response data this year. 
Fig. 3. The NS3-4A protease inhibitors telaprevir and boceprevir are 
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not achieve SVR with at least one prior course of PegIFN and 
RBV and enrolled nonresponders, relapsers, and those with 
breakthrough.
8 This phase 2 study conducted in the United 
States, Canada, and Europe enrolled 453 patients with failed 
previous IFN-based regimens due to nonresponse, and received 
either 12 weeks of telaprevir/PegIFN/RBV followed by 12 weeks 
of PegIFN/RBV, 24 weeks of telaprevir/PegIFN/RBV followed 
by 24 weeks of PegIFN/RBV, as well as a 24 week PegIFN/
telaprevir (RBV sparing) arm and the control (48 weeks PegIFN/
RBV). Nonresponders were defined as those who never achieved 
undetectable HCV RNA after a course of PegIFN and RBV of at 
least 12 weeks duration or at the end of the treatment. Relapsers 
were defined as those with undetectable HCV RNA during treat-
ment for at least 42 weeks and detectable HCV RNA levels dur-
ing follow-up. Breakthrough was defined as those who achieved 
undetectable HCV RNA during treatment but detectable levels 
of HCV RNA before end of treatment. To address the issue of 
resistance, stopping rules were defined as those with an increase 
in HCV RNA of greater than 1 log compared with nadir or an 
increase of HCV RNA to greater than 100 IU after undetect-
ability and anyone with detectable HCV RNA by week 24 was 
discontinued. In this study 40% to 49% of individuals had ad-
vanced fibrosis. The SVR was 39% in prior nonresponders with 
12 weeks of triple combination therapy followed by 24 weeks of 
PegIFN/RBV similar to the SVR rate (38%) seen with 24 weeks 
of telaprevir, PegIFN/RBV followed by 24 weeks of PegIFN/
RBV. Again, the elimination of ribavirin markedly reduced SVR 
rates with high rates of breakthrough and relapse. In relapsers, 
the SVR was 69% with 12 weeks of telaprevir, Peg IFN/RBV fol-
lowed by 12 weeks of PegIFN and RBV and 76% with48-week 
treatment with 24 weeks of telaprevir, PegIFN/RBV followed 
by 24 weeks of PegIFN/RBV. In this study, the control group 
achieved an SVR of 14%. Discontinuation rates again were 
higher in the telaprevir based arms because of rash (7%). While 
the cohort was small, 53% of cirrhotic individuals treated with 
12 weeks of telaprevir with PegIFN/RBV achieved SVR. Dropout 
rates were highest in the 48-week treatment arm with 58 of 113 
individuals discontinuing therapy suggesting that the optimal 
duration for telaprevir is 12 weeks, not 24 weeks.
4) Phase 3 studies 
Currently, phase 3 is underway and fully enrolled including 
the Advance trial with 1,050 individuals and Illuminate trial 
with 500 individuals. There is also the Realize nonresponder 
trial with 650 individuals. All of these trials will provide further 
data on the optimal use of telaprevir in those who have not 
been treated or naïve patients as well as those who failed to 
achieve SVR.
5) Emergence of drug resistance
While telaprevir and other DAA agents will substantially im-
prove SVR rates, clinicians who treat HCV infection will have to 
be cognizant of the generation of drug-resistant mutations giv-
en the high rate of replication of the HCV virus. Drug-resistant 
variants may exist as minor viral populations or quasispecies 
serves as the source of drug resistance. The resistance profiles 
are listed in Table 2. Regardless, with the addition of most DAA 
agents, it is likely that genetic resistant drug resistant mutations 
are generated immediately but these resistant mutations are 
typically associated with reduced replicative fitness, and retain 
sensitivity to PegIFN/RBV.
6) Safety and toxicity
Regarding the safety and toxicity of telaprevir, it is generally 
well tolerated, though side effects that will require careful man-
agement include gastrointestinal side effects including diarrhea, 
rash, pruritus, and anemia. These adverse events were the most 
common reasons leading to discontinuation in the telaprevir 
arms in the phase 2 studies. The rash appears in phase 2 trials to 
account for approximately 7% of all treatment discontinuations, 
and pruritus is common. Anemia is also noted with telaprevir as 
well as other DAA agents such as boceprevir. 
2. Boceprevir 
1) Preclinical studies 
Boceprevir is peptidomimetic ketoamide HCV NS3 protease 
inhibitor that binds reversibly to the NS3 active site (Fig. 3). 
Malcolm et al.
9 demonstrated a robust anti-viral activity of bo-
ceprevir in HCV replicons with treatment resulting in a 1.5 to 
2-log drop in RNA levels at 72 hours and a 3.5 to 4-log drop by 
day 1. Cells treated with boceprevir and PegIFN had a greater 
HCV replicon suppression than either agent alone and this effect 
appeared to be additive, rather than synergistic. This promising 
in vitro data allowed boceprevir to enter clinical trials.
2) Phase 1 studies 
The first of these trials was a European phase 1 clinical trial 
comparing boceprevir monotherapy to PegIFN 2b 1.5 μg/kg 
weekly and PegIFN plus boceprevir therapy in a nonresponder 
Table 2. Common Resistance Variants Reported Thus Far with Prote-
ase Inhibitors
  Site of action
Common resistant variants reported a 
position (in vitro and in vivo)
Telaprevir NS3/4a A156V/T, V36M/A+R155K/T, V36M/
A+A156V/T, V36M/A, T54A, R155K/T, 
A156S
Boceprevir NS3/4a V36M, T54S, R155K, T54A, V55A, 
R155T, A156S, V158I, V170A, V36A, 
V36L, I170T
Danoprevir NS3/4a R155K
TMC435 NS3/4a 80, 155, 156, 158
BI201335 NS3/4a 155, 156, 168410  Gut and Liver, Vol. 5, No. 4, December 2011
population.
10 Twenty-six patients with HCV genotype 1a or 1b 
who previously did not achieve EVR with PegIFN with or with-
out RBV received boceprevir monotherapy (200 or 400 mg q 8 
hours) for 1 week, PegIFN 2b 1.5 μg/kg weekly for 2 weeks and 
combination PegIFN 2b plus boceprevir for 2 weeks. Patients 
treated with PegIFN and boceprevir 200 mg q 8 hours, had a 
mean reduction in HCV RNA of -2.28 log10 and in those treated 
with PegIFN and boceprevir 400 mg q 8 hours, a mean reduc-
tion in HCV RNA of 2.68 log10 was observed with 4 patients 
clearing HCV RNA from the serum. 
3) Phase 2 studies 
With this preliminary data, a phase 2 dose-finding boceprevir 
study was initiated to determine the optimal boceprevir dose, 
whether ribavirin is required in combination with boceprevir, 
and what the optimal treatment duration would be in a null 
responder population.
11 In this study, 357 null responders who 
either failed to achieve EVR or failed to clear virus with >12 
weeks PegIFN alfa-2b/RBV therapy were enrolled and treated 
with PegIFN alfa-2b/RBV plus placebo, PegIFN alfa-2b plus bo-
ceprevir in ascending doses (100/200/400/800 mg) t.i.d. or Pe-
gIFN alfa-2b boceprevir 400 mg t.i.d. plus RBV. After an interim 
analysis by the data safety monitoring board (DSMB), the pro-
tocol was amended and all responding patients (defined as less 
than 10,000 IU/mL on original therapy) were assigned to receive 
PegIFN/RBV and boceprevir 800 t.i.d. for 24 weeks. While the 
overall SVR rate was low, this trial established several impor-
tant concepts in the treatment of HCV nonresponders with bo-
ceprevir. For treatment of null responders, ribavirin is required 
for optimal response. Boceprevir dose of 800 mg t.i.d. was safe 
when given in combination with ribavirin for 24 weeks (no 
patient initially received this dose). Finally, the null respond-
ers randomized to the PegIFN and RBV without boceprevir arm 
(control) who demonstrated interferon responsiveness (1-2 log 
reduction at week 13) were more likely to go on to achieve SVR 
with addition of boceprevir. 
These preliminary results led to the phase 2 clinical trial HCV 
Serine Protease Inhibitor Therapy-1 (SPRINT-1) evaluating bo-
ceprevir in combination with PegIFN and RBV in HCV genotype 
1 treatment naïve patients.
12 In this multi-arm trial, genotype 
1 subjects were randomized to receive PegIFN alfa-2b 1.5 μg/
kg (P), weight based RBV and boceprevir (B) 800 mg t.i.d. for 
28 or 48 weeks, or a lead-in strategy with 4 weeks of PegIFN/
RBV followed by boceprevir 800 mg t.i.d. addition to PegIFN/
RBV, and these treatment arms were compared to standard 
therapy of PegIFN/RBV for 48 weeks. The rationale for the lead-
in strategy was based on the following hypothesis: PegIFN/RBV 
reach steady-state concentrations by week 4, and with the lead 
in strategy, patients will have the protease inhibitor added when 
backbone drug levels have been optimized and the patient’s im-
mune system activated, minimizing the period of time with a 
“functional monotherapy,” potentially reducing the likelihood 
for the development of resistance to boceprevir (or other DAA). 
This strategy may also reduce the likelihood of the development 
of resistance by identifying patients who are responders to IFN 
and RBV prior to their receiving a protease inhibitor or other 
DAA drug. 
Approximately 100 subjects were enrolled in each arm and 
stratified for cirrhosis and African American race. Compared to 
PegIFN/RBV, significantly more patients in the triple therapy 
groups achieved SVR  In the 28 week treatment arms, SVR rates 
were 54% and 56% in the non-lead-in and lead-in arms, and 
in the 48 week treatment arms, SVR rates were 67% and 75% 
for non-lead-in and lead-in arms. Reducing the dose of RBV 
reduced the hematologic toxicity (anemia), but similar to tela-
previr, reduced SVR rates with high rates of breakthrough due 
to resistance. Those who cleared virus at week 4 of boceprevir 
had high rates of SVR when treated for just 28 weeks. Finally, 
response rates in African Americans, who typically have poor 
response to standard therapy, were as high as 53%. Patients 
with cirrhosis went on to SVR at rates as high as 67%.  
4) Phase 3 trials
The recently reported phase 3 Sprint-2 and Respond-2 phase 
3 trials give us further insight into the optimal use of boceprevir 
in combination with PegIFN/RBV in genotype 1 infected indi-
viduals. Sprint-1 enrolled 1,094 treatment naïve (938 nonblack 
cohort and 159 black cohort) patients into 3 treatment arms: 1) 
48 weeks of PegIFN/RBV (control), a response-guided therapy 
(RGT) arm, with 4-week lead-in followed by boceprevir for 24 
weeks with an additional 20 weeks of PegIFN/RBV if HCV RNA 
was detected during weeks 8 through 24.
13 In the third arm, pa-
tients received a PegIFN/RBV lead-in, followed by 44 weeks of 
PegIFN/RBV, and boceprevir. In both cohorts, higher sustained 
response rates were seen in the boceprevir-containing regimens, 
with the sustained response rates in the nonblack arm being 
67% for the RGT arm and 68% for the 44-week boceprevir/peg/
ribavirin arm. This was superior to PegIFN/RBV control of 40%. 
Superior sustained response rates were also seen in the black 
cohort where the response-guided therapy arm achieved an SVR 
of 42%, with the peg/ribavirin/boceprevir 44-week arm achiev-
ing an SVR of 53%, both superior to the control peg/ribavirin of 
23%. 
The nonresponder Respond-2 trial had a comparable design 
but had a longer duration of boceprevir therapy of 32 weeks 
in the response guided arm.
14 Patients received either PegIFN 
alfa-2b and ribavirin control or a 4-week lead-in followed by 
32 weeks of boceprevir, PegIFN/RBV with an additional 12 
weeks PegIFN/RBV in slow responders vs 44 weeks of PegIFN/
RBV/boceprevir after the 4-week lead-in. This nonresponder 
study included historical relapsers and partial responders (>2 
log reduction week 12), but historical null responders (<2 log 
reduction after 12 weeks of PegIFN/RBV) were excluded. Again, 
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regimens, with 59% of response-guided therapy individuals 
achieving SVR and 67% of individuals who received boceprevir 
for 44 weeks of peg/ribavirin after the lead-in achieving SVR. 
Boceprevir has now been approved for the treatment of naïve 
patients and nonresponders in combination with PegIFN and 
RBV in the United States. 
5) Safety and toxicity
Anemia and dysguesia were the most significant side effects 
noted in the boceprevir arms, though those who became ane-
mia had higher SVR rates. The use of erythropoietin (EPO) was 
permitted in this trial and higher SVR rates were noted in those 
who developed anemia and required EPO. The role of EPO with 
boceprevir is currently being studied in a randomized trial that 
is fully enrolled. The resistance profile of boceprevir is shown in 
Table 2 and is similar to that of telaprevir. 
3. Other protease inhibitors are currently in development 
The NS3/NS4A protease inhibitor ITMN-191 (R7227, dano-
previr) (Intermune, Roche) is a selective inhibitor of the NS3/
NS4 protease. As a monotherapy, ITMN-191 led to reductions 
in plasma HCV RNA in a phase 1B ascending dose study from 
100 mg q12h to 200 mg q8h and 300 mg q12h. In this study, 
maximal decreases in HCV RNA were noted in a 3.9 log10 and 
3.2 log10 in those receiving danoprevir 200 mg q8h and 200 mg 
q12h.
15 This study was followed by a preliminary presentation 
demonstrating robust HCV RNA decline with danoprevir PegIFN 
2a/RBV over 14 days with undetectable HCV RNA in up to 
57% of individuals receiving danoprevir 300 mg t.i.d.
16 Because 
a phase 2 study with danoprevir 900 mg twice a day demon-
strated Grade IV hepatotoxicity, a pilot study has been reported, 
demonstrating that ritonavir-boosted danoprevir; with, PegIFN/
RBV could lead to high rates of HCV RNA clearance with no 
hepatotoxicity. In this pilot study, 30 individuals were random-
ized to receive danoprevir 100 mg or 200 mg b.i.d. or daily with 
PegIFN/RBV. Indeed, 100% of individuals clearing HCV RNA in 
those who receive danoprevir 200 mg b.i.d. with ritonavir boost-
ing 100 mg b.i.d.
17 As ritonavir boosting has been successfully 
used in the HIV treatment, it may also serve as a useful adjunct 
to reduce HCV protease exposure and minimize toxicity. 
The NS3/NS4 protease, TMC-435 (Medavir Incorporated) 
has also been shown to be effective in treatment of genotype 1 
hepatitis C when given in combination with PegIFN and RBV. 
The initial study of TMC-435 is a macrocyclic HCV NS3/NS4A 
protease inhibitor, with a favorable pharmacokinetic profile 
supporting once daily dosing. A small pilot study demonstrated 
a median of 3.9 log10 reduction in HCV RNA after 5 days of 
monotherapy in individuals who had failed previous interferon-
based therapy.
18 A phase 2A study with TMC435 (Opera 1) has 
been reported. In this study, TMC435, was combined in ascend-
ing doses from 75 mg to 200 mg for 4 weeks, in combination 
with PegIFN/RBV in treatment naïve and treatment experienced 
individuals (nonresponders and relapsers). At week 4, 44%, 
78%, and 70% of individuals in the 75, 150, and 200 mg daily 
treatment groups, achieved plasma HCV RNA levels of <25 IU, 
with relapsers responding with higher rates of HCV RNA clear-
ance than nonresponders. TMC435 was well tolerated, though 
elevated serum bilirubin levels (total direct and indirect), pri-
marily with the 200 mg dose were noted.
19 Current studies are 
ongoing with TMC in combination with PegIFN alfa-2a and 
ribavirin in the Pillar study and Aspire study, and we await 
further results for this promising compound which can be given 
daily. The preliminary resistance profile is listed in Table 2, with 
mutations at NS3 amino acid position 80, 155, 156, and 158 be-
ing reported.
The NS3 protease inhibitor BI201335 is a potent HCV NS34A 
inhibitor with preliminary results demonstrating improved 
viral clearance rates through week 12. In the Silen-C1 study, 
BI201335 was added to PegIFN2a180/RBV at doses of 240 and 
120 mg daily in treatment naïve patients. In this study, RVR 
rates ranging from 90% to 92% (dose independent) and com-
plete EVR ranging from 84% to 91% were noted.
20 The Silen-C2 
study used higher doses of BI201335 (240 mg and 240 mg b.i.d.) 
in combination with PegIFN/RBV in nonresponders who failed 
previous PegIFN/RBV. The 12-week analysis was recently pre-
sented with RVR rates of 62% to 69% seen in the 240 b.i.d. with 
3-day PegIFN/RBV lead-in and EVR rates ranging from 54% 
to 59%.
21 Similar to the Silen-1 study, an increased incidence 
of jaundice and rash were noted. The final SVR rates for these 
2 studies is currently being awaited. Amino acid changes were 
most commonly seen as residues 168, 156, and 155.
POLYMERASES AS POTENTIAL TARGES OF ANTI-HCV 
THERAPY
1. NS5B polymerase inhibitors
The HCV replication process is complex and therefore offers a 
wide variety of targets for antiviral intervention other than the 
NS3/NS4 protease. As a class, the development of inhibitors of 
NS5b is not as mature as that of the NS3/NS4a protease inhibi-
tors. Nonetheless, preliminary data suggest that this will be an 
effective class of agents in the treatment of HCV infection. In 
contrast to NIs, the heterogeneous class of nonnucleoside in-
hibitors (NNIs) bind to different allosteric enzyme sites, which 
results in conformational protein change before the elongation 
complex is formed. NNIs achieve NS5B inhibition by binding to 
1 of multiple allosteric enzyme sites resulting in conformational 
changes of the protein-inhibiting catalytic activity of poly-
merase.
22-25 They have genotype-specific activity and potential 
for rapid selection of resistance. The rapid development of resis-
tant mutants is possible with non-nucleoside inhibitors because 
they bind distantly to the active center of NS5B and mutations 
at the non-nucleoside inhibitor binding site may not necessarily 
lead to impairment of the enzyme function. Due to their distinc-412  Gut and Liver, Vol. 5, No. 4, December 2011
tive binding sites, different polymerase inhibitors could theoreti-
cally be used in combination to reduce the risk of development 
of resistance (Table 3, Fig. 4).
1) Nucleoside inhibitors
(1) RG7128 
RG7128 is the oral prodrug of PSI-6130, a second cytidine 
nucleoside analogue under clinical development and has dem-
onstrated potent in vitro activity regardless of race, ethnicity 
and genotype. Thus far, viral resistance has not been detected in 
any clinical trials with RG7128, which suggests that the nucleo-
side class may offer a higher genetic barrier to viral resistance 
than the protease class of inhibitors. In a dose-escalating phase 
1b trial, a dose-dependent decrease in HCV RNA was observed 
in genotype 1 previous nonresponders.
26 RG7128 is well toler-
ated as monotherapy and no serious AEs were reported in any 
study arm. In treatment naïve genotype 1 patients, the combi-
nation of R7128 (1,500 mg b.i.d. in combination with PegIFN/
RBV achieved a reduction in HCV RNA of approximately 5 log10 
at 4 weeks translating into a RVR rate of 85% (vs 2 log10 IU/
mL and 10% in control arm).
27 No virological rebound was ob-
served during R7128 treatment to 4 weeks. Importantly, R7128 
was generally well tolerated in combination with PegIFNa and 
RBV. The grade 3/4 hematological toxicity was rare and head-
ache, fatigue, and chills were classified as mild AEs. Preliminary 
resistance testing failed to identify any variants to week 4 and 
this trial is ongoing. The combination of a potent anti-viral ef-
fect and satisfactory toxicity profile makes R7128 an attractive 
agent. 
In addition, it is the first polymerase inhibitor being tested 
for anti-viral activity against genotypes 2 and 3 HCV. A small 
study done recently showed higher SVR with RG7128 plus Pe-
gIFNa/RBV in genotypes 2 and 3 HCV patients who previously 
failed PegIFNa/RBV treatment.
28 This randomized trial compar-
ing RG7128 (n=20) with placebo (n=5), each in combination 
with PegIFN/RBV for 4 weeks followed by continued PegIFN/
RBV treatment for a total of 24 to 48 weeks, depending on the 
patient’s previous response to therapy and achievement of RVR 
in the current trial. The RVR rate was 95% with RG7128 triple 
therapy vs 60% with PegIFNa/RBV and the SVR rates were 65% 
vs 60%, respectively. Higher SVR rates with RG7128 treatment 
were associated with achieving RVR and longer duration of 
PegIFNa/RBV therapy, whereas HCV genotype did not impact 
the likelihood of SVR with 63% of genotype 2 patients with 
Table 3. Polymerase Inhibitors for Hepatitis C Virus: Drugs in Development
Drug name Company Target/Active drug
Current phase of 
the trial
Nucleoside analogue NS5B polymerase inhibitors
   Valopicitabine (NM283) Idenix/Novartis Active site/NM107 Stopped 
   R7128 Roche/Pharmasset Active site/PSI-6130 Phase 2
   R1626 Roche Active site/PSI-6130 Stopped
   PSI-7851 Pharmasset Active site Phase 1
   IDX184 Idenix Active site Phase 2
Nonnucleoside NS5B polymerase inhibitors (NNI)
   BILB 1941 Boehringer Ingelheim NNI site 1/thumb 1 Stopped
   BI207127 Boehringer Ingelheim NNI site 1/thumb 1 Phase 2
   MK-3281 Merck NNI site 1/thumb 1 Stopped
   Filibuvir (PF-00868554) Pfizer NNI site 2/thumb 2 Phase 2
   VCH759 ViroChem Pharma NNI site 2/thumb 2 Phase 1
   VCH916 ViroChem Pharma NNI site 2/thumb 2 Phase 1
   VCH222 ViroChem Pharma NNI site 2/thumb 2 Phase 1
   HCV-796 ViroPharma/Wyeth NNI site 4/palm 2 Stopped
   ANA598 Anadys NNI site 3/palm1 Phase 1
   GS-9190   Gilead NNI site 4/palm2 Phase 2
   VX-222 Vertex  NNI site 2/thumb 2 Phase 1b
   ABT-333 Abbott NNI site 4/palm2 Phase 1
NS5A inhibitors
   BMS-790052 Bristol-Myers Squibb NS5A domain 1 inhibitor Phase 2
   A832 Astra Zeneca NS5A inhibitor Phase 1
   AZD7295 Astra Zeneca NS5A Inhibitor Phase 2Kwo PY, et al: The Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase Inhibitors  413
achieving SVR vs 67% of patients with genotype 3. The higher 
RVR rates but similar SVR rates with RG7128 triple therapy vs 
PegIFNa/RBV in this study suggest that polymerase inhibitor 
treatment will need to be administered for longer than 4 weeks 
in previous nonresponders with genotype 2 and particularly 
genotype 3 infection. 
The novel study INFORM-1, the first dual combination clini-
cal trial with oral antivirals in HCV patients evaluated the safety 
and combined antiviral activity of RG7227, a protease inhibitor 
and RG7128, a polymerase inhibitor, in 14 days of combination 
therapy in treatment-naïve patients, experienced non-null or 
null-responders infected with HCV genotype 1.
29 The basis of 
this trial is that induction therapy with potent DAA regimens 
could potentially enhance the efficacy and decrease the dura-
tion of treatment with the current treatmentfor chronic hepatitis 
C (PegIFN/RBV). Patients receiving this combination for 14 days 
experienced a median reduction in viral levels of 4.8 to 5.2 log10 
IU in the higher doses tested and this combination was equally 
effective in both naïve and previous nonresponders with the 
lowest reductions observed in treatment-naïve patients receiv-
ing the lowest drug doses and in previous nonresponders (ex-
cluding null responders). The highest end-of-treatment response 
rate in treatment-naïve individuals (100%) was achieved in pa-
tients treated with the highest dosage combination of RG7128/
RG7227 (1,000/900 mg b.i.d.). All patients achieved an RVR at 
week 4 of treatment with PegIFN/RBV were assigned to an ab-
breviated 24-week regimen. These encouraging results provide 
a proof of concept that, when given at optimal doses, a short 
course of dual combination therapy can be highly effective in 
suppressing HCV RNA in the absence of PegIFN/RBV. Impor-
tantly, no drug resistant mutations emerged during the 14-day 
treatment period in any patient group. No treatment-related se-
rious adverse events, dose reductions, drug-drug interactions or 
discontinuations were reported. Given these encouraging data, 
combinations of DAA agents in the absence of PegIFN and/or 
RBV will be undertaken. 
(2) Other nucleoside/nucleotide inhibitors (NIs) 
Several other new NIs are currently under various stages of 
clinical trials including IDX184, liver-targeted nucleotide NS5B 
polymerase inhibitor.
30 PSI-7851, a second generation nucleo-
tide inhibitor and PSI-7977, an isomer of PSI-7851. A phase 2 
study of PSI-7977 administered once-daily in combination with 
PegIFNa/RBV for 28 days in 63 previously untreated patients 
with genotype 1 chronic hepatitis C with PegIFN/RBVcontinued 
for an additional 44 weeks. PSI-7977 has been enrolled and fur-
ther results are expected later this year.
31
2. Nonnucleoside analogue inhibitors 
1) NNI-site 1 inhibitors (thumb 1/benzimidazole site) (Fig. 4)
BILB1941, BI207127, and MK3281 are NNI-site 1 inhibi-
tors which have been investigated in clinical phase 1 trials and 
exhibit low to medium anti-viral activities.
32-34 No selection of 
Fig. 4. Binding sites of various nucleoside and nonnucleoside inhibitors. The hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp) 
is a key enzyme involved in HCV replication, catalyzing the synthesis of the complementary minus-strand RNA and subsequent genomic plus-
strand RNA from the minus-strand template. The NS5B polymerase inhibitors for treatment of chronic hepatitis C can be divided into 2 distinct 
categories: 1) nucleoside or nucleotide inhibitors (active site inhibitors), and 2) nonnucleotide inhibitors (allosteric inhibitors). Nucleoside ana-
logues mimic the natural substrates of the polymerase and are incorporated into the growing RNA chain, thus causing direct chain termination 
by tackling the active site of NS5B. As the active center of NS5B is a highly conserved region of the HCV genome, NIs are potentially effective 
against different genotypes, in contrast to NS3/4A inhibitors. Moreover, single amino acid substitutions in every position of the active center may 
result in loss of function and severely reduce replication fitness. Thus, there is a relatively high genetic barrier in the development of resistances to 
NIs, a desirable trait for anti-HCV direct-acting antiviral agent. Adapted from Butcher et al. Nature 2001;410:235-40.414  Gut and Liver, Vol. 5, No. 4, December 2011
resistant variants and viral breakthrough has been observed 
during 5 days of treatment with BILB1941 or BI207127. Gas-
trointestinal intolerance at higher doses, elevated liver enzymes, 
and its liquid formulation led to a halt in further development 
of BILB1941. In a recent double-blind placebo-controlled study, 
7 days of MK-3281 monotherapy in genotype 1/3 HCV male 
patients resulted in rapid and significant HCV RNA reductions 
vs placebo with the greatest degree of virologic suppression in 
genotype 1b HCV patients and no serious clinical or laboratory 
adverse events were reported. 
2) NNI-site 2 inhibitors (thumb 2/thiophene site) (Fig. 4)
Filibuvir (PF-00868554) is a NNI-site 2 inhibitor with moder-
ate anti-viral activity in a phase 1 study. In a subsequent trial 
viral breakthrough was observed in 5 of 26 patients during 
combination therapy with PegIFN-a 2a and RBV for 4 weeks.
35 
A phase 2, randomized, double-blind, placebo-controlled study 
to evaluate the safety and efficacy of filibuvir plus PegIFN-a 
2a/RBV in treatment-naïve, HCV genotype 1 infected subjects 
is currently underway. Other NNI-site 2 inhibitors which were 
evaluated in phase 1 trials are VCH-759, VCH-916, and VCH-
222. Like during treatment with filibuvir, VCH-759 and VCH-
916 application resulted in viral breakthroughs with selection of 
resistant variants, indicating a lower genetic barrier to resistance 
of these agents as opposed to the NIs. Preliminary results from 
a randomized, placebo-controlled phase Ib/IIa dose-escalation 
study of the novel nonnucleoside HCV NS5B polymerase in-
hibitor VX-222 were recently reported.
36 VX-222 monotherapy 
was associated with >3.0 log10 IU/mL mean decreases in HCV 
RNA from baseline to day 3 at all doses evaluated, suggesting 
that this agent represents one of the most potent nonnucleo-
side polymerase inhibitors tested to date. Reductions in HCV 
RNA levels were observed within 1 day of VX-222 initiation 
in all cohorts, including in patients infected with genotypes 1a 
and 1b HCV. This finding is important because nonnucleoside 
polymerase inhibitors often have differential activity toward 
HCV genotypes 1a and 1b. The most frequent adverse events 
included diarrhea headache and nausea with no serious adverse 
events were reported.
3) NNI-site 3 inhibitors (palm 1/benzothiadiazine site)
ANA598 is a NNI-site 3 inhibitor which displayed antiviral 
activity during treatment of HCV genotype 1 infected patients 
when combined with PegIFN/RBV.
37 A larger phase 2 trial is 
planned. IDX375 demonstrated strong inhibition of HCV repli-
cation (EC50=2.3 nM) in the subgenomic replicon system, with 
no in vitro cytotoxicity in rat, mouse, monkey, and human he-
patocytes, and no apparent in vivo adverse events in monkeys 
and is continuing clinical development.
38
4) NNI-site 4 inhibitors (palm 2/benzofuran site)
ABT-333, another palm site inhibitor, has demonstrated a 
promising in vitro antiviral profile, with enzyme inhibition 
IC50 levels of 2.2 nM against HCV genotypes 1 and 2 and EC50 
values of 0.5 to 0.8 nM in the context of the replicon system 
against HCV genotypes 1a and 1b.
39 Recent data on the phar-
macokinetic profile, safety, and efficacy of ABT-333 treatment-
naïve patients infected with genotype 1 HCV is promising and 
is being investigated further in combination with PegIFN/RBV. 
The NNI site 4 inhibitor GS-9190 displays anti-viral activity 
in a clinical study and variants conferring resistance were iden-
tified in the beta-hairpin of the polymerase.
40,41 Preliminary data 
of 23 study participants who received multiple ascending doses 
over 8 days suggested that GS 9190 may be associated with QT 
prolongation. After consultation and a separate dose-ranging 
study in healthy volunteers, the QT prolongation at a lower dose 
of the drug was determined to be “clinically manageable” (Gilead 
Quarterly Report, May 2, 2008). GS-9190 is currently the most 
advanced NS5B polymerase NNI (phase 2) and a study in com-
bination with PegIFN/RBV is currently underway with results to 
be reported in the next year.
3. NS5A inhibitors
The function of HCV NS5A is not fully defined. Two potent 
NS5A specifically targeted antiviral therapy compounds have 
been evaluated in clinical trials, including compounds A-832 
(phase 1) and BMS-790052 (phase 2). BMS-790052 binds to 
domain I of the NS5A protein, which was shown to be impor-
tant for regulation of HCV replication. It is highly potent selec-
tive inhibitor of NS5A, and has shown strong activity against 
several genotypes in both replicon and JFH-1 systems.
42 The in 
vitro potency is extremely high with a half maximal effective 
concentration in the range of 9-127 pM, depending on the viral 
genotype. This value reflects 100- to 1,000-fold higher potency 
than most other drugs that are being investigated. The results 
of a previous single ascending-dose study of BMS-790052 in 
patients infected with genotype 1 HCV were striking in that 
patients who received a single 100-mg dose exhibited an ap-
proximately 3.6 log10 mean reduction in HCV RNA that was 
maintained 144 hours after dosing.
43 A week 12 data from a 
randomized, placebo-controlled, phase IIa trial investigating dif-
ferent once-daily BMS-790052 doses (3 mg, 10 mg, and 60 mg) 
in combination with PegIFNa/RBV for 48 weeks in treatment-
naïve patients infected with genotype 1 HCV was recently 
reported.
44 The preliminary results study (n=48) demonstrated 
high RVR rates of 92% and 83% with BMS-790052 doses of 
10 mg and 60 mg, respectively, in combination with PegIFNa/
RBV. Complete EVR rates were similarly high at 83% in both 
the 10-mg and 60-mg dosing arms. Patients treated with BMS-
790052 3 mg daily experienced lower RVR and complete EVR 
rates of 42% and 58%, respectively. The adverse event profile 
at this early stage appears favorable. This preliminary analysis 
suggests that this drug class may be promising for patients with 
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observed across other genotypes. The resistance profile of BMS-
790052 is well characterized in replicon systems but there is 
limited data from the preliminary clinical trials. Other NS5A 
inhibitors such as PPI-461 and AZD 7295 are also in clinical 
development phase and results look encouraging.
45,46 No clinical 
data on resistance to this class of drugs have been presented yet 
and results of multiple dose and combination therapy studies 
have to be awaited.
CONCLUSION AND FUTURE DIRECTIONS
In summary, it is very likely that the NS3/NS4a protease 
inhibitors will be approved next year by regulatory agencies 
in the United States and Europe for use in combination with 
PegIFN/RBV. This will dramatically improve SVR rates but in 
those who are poorly interferon responsive, the risk of resis-
tance will remain. Preliminary results suggest that the addition 
of nucleoside polymerase inhibitors to PegIFN/RBV will also 
lead to high SVR rates and the nucleoside polymerase inhibitor 
class may be a particularly attractive backbone therapy for the 
treatment of hepatitis C. Finally, preliminary data with the NS5a 
inhibitor class appears to be highly promising when given in 
combination with PegIFN and RBV. In the future, combination 
of DAAs including polymerase inhibitors both nucleoside, and 
nonnucleoside, protease inhibitors, and NS5a inhibitors to Pe-
gIFN, and RBV will likely significantly reduce resistance rates, 
and it is anticipated that the combinations of DAAs will im-
prove SVR rates further in combination with PegIFN and RBV 
likely by reducing the risk of developing resistance. Moving for-
ward, the ability to eliminate IFN and/or RBV in the future and 
still achieve SVR will be the next major goal in the treatment of 
hepatitis C.
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